NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
about
Adaptations of the Secretome of Candida albicans in Response to Host-Related Environmental ConditionsSystemic Staphylococcus aureus infection mediated by Candida albicans hyphal invasion of mucosal tissue.Experimental Models of Vaginal Candidiasis and Their Relevance to Human CandidiasisCandida vaginitis: when opportunism knocks, the host respondsApplying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Fungal vaccines and immunotherapeutics.Mechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.Exploiting fungal cell wall components in vaccinesVaccines in the treatment of invasive candidiasis.Adaptive immune responses to Candida albicans infection.Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor EffectProteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins.Innate immune cell response upon Candida albicans infectionCandida antigens and immune responses: implications for a vaccine.The Candida pathogenic species complex.Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis.IL-17 Receptor Signaling in Oral Epithelial Cells Is Critical for Protection against Oropharyngeal Candidiasis.Glucosamine stimulates pheromone-independent dimorphic transition in Cryptococcus neoformans by promoting Crz1 nuclear translocation.Accessibility and contribution to glucan masking of natural and genetically tagged versions of yeast wall protein 1 of Candida albicans.Patient Susceptibility to Candidiasis-A Potential for Adjunctive Immunotherapy.A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial.Human Anti-Als3p Antibodies Are Surrogate Markers of NDV-3A Vaccine Efficacy Against Recurrent Vulvovaginal Candidiasis.Candida Immunity
P2860
Q26785119-06A78998-B4BC-4F2E-AA75-EC5600728419Q27323146-C6EE4A5B-590C-4CC8-B207-72C0D3669D72Q28077299-B27D3130-ACD9-4872-884F-50A9BFA0126CQ31157510-C0308194-8BAD-446F-A021-EBF1BF988F50Q34250054-197426C9-158D-4B0D-AB8E-5235F128CB90Q34400249-A31FA268-2981-4CE1-95C8-B047D5EB3570Q34792962-7C023E8C-A256-4E2C-9710-3A275591E7F2Q35085200-FD929419-95E5-4D47-A40A-7E11E99CC2C8Q36147010-9C50EE4C-F867-4A59-9CC1-C5E8511FC7E6Q36147114-32748D4A-1A3B-447A-9544-F14AD3A66B8FQ36162804-69928489-2CC2-44A9-AAC5-9C2CAB47EE78Q36562397-4005AA9E-7DFF-451B-B874-C392F7CFD380Q37262877-8191BC64-7E40-4561-AFA4-F2368FA1A2AAQ38222636-A76CB15C-8F9E-46E7-886C-9DBDB00A2C23Q38245727-359BEF66-1854-416B-9130-AE7EB4A02127Q40183727-CEC9961F-E2F6-4762-8746-432230D0BB07Q40421383-03CC81EC-0A0A-464F-A40A-0A63A4D67EB8Q41229705-99984AFA-8D4D-4C99-9B28-42F6690DA3BAQ48252614-EB6350F6-4D24-49FD-A7E9-4CEAAC80C6DFQ49679946-0CAC6C75-E344-4E50-9DA7-F336C1D0FEECQ52561594-2DC12F26-F137-42FA-91BA-B4643B9910D6Q55396489-061DC749-624B-48FC-A146-6773CD575EA5Q59072636-CBF43905-8154-4D87-85B8-17628B9CF8C4
P2860
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
@en
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
@nl
type
label
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
@en
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
@nl
prefLabel
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
@en
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
@nl
P2093
P2860
P1433
P1476
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
@en
P2093
Ashraf S Ibrahim
Clint S Schmidt
Guanpingsheng Luo
Hongkyu Lee
John E Edwards
Michael R Yeaman
Samuel W French
Scott G Filler
Teclegiorgis Gebremariam
P2860
P304
P356
10.1016/J.VACCINE.2013.09.016
P407
P577
2013-09-21T00:00:00Z